Develops a platform for the oral delivery of therapeutic proteins, led by an oral insulin candidate, and intends to earn upfront fees, development milestones and royalties by out-licensing that technology to pharmaceutical partners and distributors.
Geographic Exposure
IsraelN/A
Revenue Drivers
End Markets
Pharmaceutical licensees
Pharmaceutical distributors
HTIT
Medicox
Entera Bio
Specializations
Oral delivery of therapeutic proteinsGastric-resistant oral dosage formulationOral exenatide formulationPatient-subpopulation Phase 3 protocol designMulti-jurisdiction patent prosecution and protectionOral vaccine development via majority-owned venture
